Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that it completed enrollment in the first stage of its adaptive Phase 2 trial to evaluate PRM‐151, its lead product candidate, in patients with myelofibrosis. The Phase 2 trial rapidly completed enrollment, enrolling 25 patients in just over 12‐weeks. Formally initiated in October 2013 at several sites in the United States and Canada, this first stage is expected to be completed in 2014.